Search

Twist Bioscience Corp

Slēgts

SektorsVeselības aprūpe

184.03 15.92

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

156.83

Max

165.78

Galvenie mērījumi

By Trading Economics

Ienākumi

9M

-35M

Pārdošana

7.7M

118M

EPS

-0.56

Peļņas marža

-29.61

Darbinieki

979

EBITDA

9.8M

-28M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-28.39% downside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 13. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

4.7B

11B

Iepriekšējā atvēršanas cena

168.11

Iepriekšējā slēgšanas cena

184.03

Ziņu noskaņojums

By Acuity

50%

50%

128 / 339 Rangs Healthcare

Twist Bioscience Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. sept. 20:07 UTC

Twist Bioscience Corp shares fell sharply on Wednesday, closing significantly lower after a brief recovery, marking three consecutive sessions of declines.

2026. g. 22. sept. 23:05 UTC

Twist Bioscience Corp remained roughly flat in after-market trading, fluctuating around unchanged while significantly above its 20-day moving average.

2026. g. 21. sept. 23:06 UTC

Social Media

Twist Bioscience shares are trading modestly lower in after-market hours following CEO Emily M. Leproust's $55.40 million stock sale on September 17.

2026. g. 18. sept. 20:03 UTC

News
Social Media

Twist Bioscience Corp's stock is rising after a partnership with Eli Lilly’s TuneLab and Leerink raised its price target to $160 from $120.

2026. g. 17. sept. 23:06 UTC

News

Twist Bioscience Corp's stock rises after a partnership with Eli Lilly's TuneLab, with Leerink raising its price target to $160 and increased fiscal 2026 sales guidance.

2026. g. 16. sept. 23:01 UTC

Twist Bioscience Corp's shares have declined in after-market trading, reaching their lowest level since Wednesday's close despite previous upward momentum.

2026. g. 15. sept. 23:02 UTC

Twist Bioscience Corp shares are lower in after-market hours following a significant decline in the New York Empire State Manufacturing Index, which missed expectations.

2026. g. 14. sept. 20:07 UTC

Twist Bioscience Corp is higher during Monday's session, recovering from earlier losses. No specific news was identified to explain the price movement.

2026. g. 11. sept. 20:08 UTC

Social Media

Twist Bioscience shares are higher after being identified for bullish potential, supported by a MACD pinch technical indicator. The stock advanced despite earlier session dips.

2026. g. 10. sept. 23:01 UTC

Twist Bioscience Corp shares are trading higher in after-market hours. No specific news was identified to explain the movement.

2026. g. 9. sept. 20:07 UTC

News
Correlated Moves

Twist Bioscience shares are lower as BWS Financial initiates coverage with a Sell rating, contrasting UBS's Neutral rating and higher price target of $144.00.

2026. g. 8. sept. 20:07 UTC

News
Social Media

Twist Bioscience Corp shares are higher, driven by increased recognition of AI applications in healthcare and a "Moderate Buy" consensus rating from brokerages.

2026. g. 3. sept. 19:36 UTC

News

Twist Bioscience reported $118.4 million in Q3 revenue and raised its guidance, yet shares are lower, continuing a five-session decline.

2026. g. 2. sept. 23:06 UTC

Twist Bioscience Corp. shares are lower in after-market hours, extending a trend of five consecutive daily declines. Earlier, the stock briefly rose before falling again.

2026. g. 1. sept. 19:56 UTC

Correlated Moves

Twist Bioscience Corp shares are lower amid broader market pressures and rising Treasury yields. The Russell 2000 Index also declined during Tuesday's session.

2026. g. 31. aug. 23:46 UTC

Twist Bioscience Corp shares are lower in after-market trading, following no specific news. The stock remains above its 20-day moving average.

2026. g. 28. aug. 22:51 UTC

Twist Bioscience shares are higher in after-market trading. Rising Treasury yields may be influencing investor sentiment in the biotechnology sector.

2026. g. 27. aug. 23:02 UTC

Twist Bioscience shares are higher in after-market hours, recovering from earlier losses. Jobless claims data suggests strength in the labor market.

2026. g. 26. aug. 19:36 UTC

Twist Bioscience Corp shares are trading higher today, maintaining a position near the upper end of their one-month range. No specific news has been identified.

2026. g. 25. aug. 23:06 UTC

Twist Bioscience Corp shares are higher in after-market hours, rebounding from a post-close low amid broader market support from falling crude oil prices and treasury yields.

2026. g. 24. aug. 23:51 UTC

Twist Bioscience Corp shares are higher in after-market trading, maintaining gains from earlier in the session and staying above key moving averages.

2026. g. 21. aug. 23:46 UTC

Twist Bioscience Corp shares are lower in after-market trading, despite remaining well above their 20-day moving average and last month's price levels.

2026. g. 20. aug. 23:46 UTC

Twist Bioscience Corp shares are lower in after-market trading. Broader market pressures, including rising crude oil prices and geopolitical tensions, may be influencing sentiment.

2026. g. 19. aug. 23:06 UTC

News
Correlated Moves

Twist Bioscience Corp shares are lower in after-market hours following a critical short report from Scorpion Capital questioning the company's AI-driven protein design strategy.

2026. g. 18. aug. 23:21 UTC

Twist Bioscience Corp shares are higher in after-market trading, maintaining an upward trend and positioned above its 20-day moving average.

2026. g. 17. aug. 22:36 UTC

Twist Bioscience Corp shares are slightly higher in after-market hours, maintaining strong performance above their 20-day moving average despite earlier declines.

2026. g. 14. aug. 19:06 UTC

Twist Bioscience shares are lower today, continuing a decline since Thursday amid broader market volatility and recent U.S. retail sales data.

2026. g. 13. aug. 23:06 UTC

Correlated Moves

Twist Bioscience Corp shares are lower in after-market trading, influenced by broader market declines and recent macroeconomic data on jobless claims and producer prices.

2026. g. 12. aug. 19:16 UTC

Twist Bioscience Corp is higher Wednesday, tracking broader U.S. stock gains amid strength in AI sectors following positive quarterly results from CoreWeave and Super Micro Computer.

2026. g. 11. aug. 23:46 UTC

Correlated Moves

Twist Bioscience Corp shares declined during after-market hours, following a drop in the Russell 2000 Index amid investor caution ahead of the consumer price index report.

Salīdzinājums

Cenas izmaiņa

Twist Bioscience Corp Prognoze

Cenas mērķis

By TipRanks

-28.39% uz leju

Prognoze 12 mēnešiem

Vidējais 113.5 USD  -28.39%

Augstākais 160 USD

Zemākais 45 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Twist Bioscience Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

8

Pirkt

2

Turēt

1

Pārdot

Noskaņojums

By Acuity

128 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.